Home  |  Contact

Cellosaurus K562/GM-CSF (CVCL_A8HT)

[Text version]

Cell line name K562/GM-CSF
Synonyms K562 GM-CSF; K562GM-CSF; GM-K562
Accession CVCL_A8HT
Resource Identification Initiative To cite this cell line use: K562/GM-CSF (RRID:CVCL_A8HT)
Comments Biotechnology: Used for the production of the Sorento Therapeutics STI-6991 SARS-CoV-2 (COVID-19) vaccine candidate. The cell line which is lethally irradiated is used to produce the recombinant SARS-CoV-2 spike protein rSARS-CoV-2 which is the active part of the vaccine formulation (PubMed=32289117).
Characteristics: Does not express HLA class I or II antigens, potentially decreasing the magnitude of the alloresponses generated on repeated immunizations (PubMed=10466632).
Transfected with: HGNC; 2434; CSF2.
Transfected with: UniProtKB; P00557; E.coli hygromycin-B 4-O-kinase (hph).
Derived from sampling site: Pleural effusion.
Sequence variations Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line).
Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
Disease Blast phase chronic myelogenous leukemia, BCR-ABL1 positive (NCIt: C9110)
Chronic myeloid leukemia (ORDO: Orphanet_521)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0004 (K-562)
Sex of cell Female
Age at sampling 53Y
Category Cancer cell line
Publications

PubMed=10466632; DOI=10.1089/10430349950017347
Borrello I., Sotomayor E.M., Cooke S., Levitsky H.I.
A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines.
Hum. Gene Ther. 10:1983-1991(1999)

PubMed=23170257; DOI=10.4161/onci.20954
Brusic A., Hainz U., Wadleigh M., Neuberg D., Su M., Canning C.M., Deangelo D.J., Stone R.M., Lee J.-S., Mulligan R.C., Ritz J., Dranoff G., Sasada T., Wu C.J.
Detecting T-cell reactivity to whole cell vaccines: proof of concept analysis of T-cell response to K562 cell antigens in CML patients.
OncoImmunology 1:1095-1103(2012)

PubMed=32289117; DOI=10.1016/j.medidd.2020.100026
Ji H., Yan Y., Ding B.-B., Guo W.-Z., Brunswick M., Niethammer A., SooHoo W., Smith R., Nahama A., Zhang Y.-L.
Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing cells as immune presenter and adjuvant in vaccine prototype against SARS-CoV-2 virus.
Med. Drug Discov. 5:100026-100026(2020)

Entry history
Entry creation20-May-2021
Last entry update20-May-2021
Version number1